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Pngiotensin-Converting Enzyme Inhibitor
s a Risk Factor for the Development of
nemia, and the Impact of Incident Anemia on
ortality in Patients With Left Ventricular Dysfunction
reef Ishani, MD,* Eric Weinhandl, MS,† Zihong Zhao, MS,† David T. Gilbertson, PHD,†
llan J. Collins, MD,†‡ Salim Yusuf, MD,§ Charles A. Herzog, MD†‡
inneapolis, Minnesota; and Hamilton, Canada
OBJECTIVES We aimed to investigate the impact of angiotensin-converting enzyme inhibitors (ACEIs) on
hematocrit values in those with heart failure, and the relationship between incident anemia
and mortality.
BACKGROUND Prevalent anemia is an independent risk factor for morbidity and mortality in those with heart
failure. Studies in patients with polycythemia have demonstrated that ACEIs are effective in
lowering hematocrit values.
METHODS We used the Studies Of Left Ventricular Dysfunction (SOLVD) database to compare the
odds of developing new anemia at one year in patients who were not anemic at entry and who
were randomized to enalapril or placebo. Cox proportional hazards models were utilized to
determine the impact of incident and prevalent anemia on subsequent mortality.
RESULTS Enalapril increased the odds of incident anemia (hematocrit 39% in men or 36% in
women) at one year by 48% (odds ratio [OR] 1.48, 95% confidence interval [CI] 1.20 to 1.82)
in unadjusted and 56% (OR 1.56, 95% CI 1.26 to 1.93) in adjusted models. With multivariate
analysis, prevalent anemia at randomization was associated with a 44% (hazard ratio [HR]
1.44, 95% CI 1.31 to 1.66) increase in all-cause mortality, whereas incident anemia after
randomization was associated with a 108% increase (HR 2.08, 95% CI 1.82 to 2.38). After
adjusting for incident and prevalent anemia, use of enalapril was associated with a survival
benefit.
CONCLUSIONS Enalapril was associated with increased odds of developing anemia at one year. Those with
periods of time with incident anemia had the poorest survival, followed by those with
prevalent anemia, then those without anemia. Enalapril was protective of overall mortality
after adjusting for incident anemia and in those with prevalent anemia. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.0382005;45:391–9) © 2005 by the American College of Cardiology Foundation
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tt is estimated that more than 4.8 million individuals have
een diagnosed to have heart failure (HF) in the U.S. alone
1). In addition, there are 550,000 new cases of HF
iagnosed annually (2). A recent study has demonstrated
hat the incidence of HF over time is unchanged in men and
as improved only slightly in women (3). Improving the
urvival of those with HF is of significant public health
mportance.
An under-recognized risk factor for mortality in patients
ith HF has been anemia. A recent retrospective cohort
tudy demonstrated that even a relatively mild decline in
emoglobin was associated with a reduced functional status
nd a higher mortality (4). An analysis of the participants in
he Studies Of Left Ventricular Dysfunction (SOLVD) trial
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Manuscript received July 27, 2004; revised manuscript received September 21,
004, accepted October 4, 2004.emonstrated that for each 1% lower pre-randomization
ematocrit value, the risk of dying increased by 6% (5).
urrent guidelines on the treatment of HF make no
ention of the impact of anemia on the morbidity or
ortality of HF (6).
Multiple studies have documented the efficacy of
ngiotensin-converting enzyme inhibitors (ACEIs) in re-
ucing the morbidity and mortality associated with HF.
onsequently, the current standard for therapy in those
ith HF is a cocktail of medications, a key component of
hich is an ACEI (6). Studies in those with polycythemia
ave demonstrated that both ACEIs and angiotensin recep-
or blockers (ARBs) are effective therapeutic agents in
educing hemoglobin concentrations (7–9). The mechanism
hrough which ACEIs cause a decline in hemoglobin
oncentration remains unclear; however, it is postulated that
oth ACEIs and ARBs inhibit growth of erythroid precur-
ors (10). Currently, there exists very little information
egarding the effect of ACEIs on hematocrit values in those
ith either normal hemoglobin concentrations or in those
ith HF.
The Studies Of Left Ventricular Dysfunction (SOLVD)
rial was a large randomized trial evaluating the effect of
nalapril therapy on mortality in those with asymptomatic
l
U
e
i
2
w
e
p
M
A
w
c
p
m
P
t
e
a
w
t
d
s
f
p
Y
w
s
q
c
2
v
e
a
w
p
r
t
w
d
(
m
w
s
w
c
o
p
w
p
t
a
g
a
(
p
p
d
m
e
t
w
e
t
m
a
t
b
d
i
a
r
i
c
v
c
o
a
t
a
p
m
s
e
p
S
p
c
C
s
R
T
t
392 Ishani et al. JACC Vol. 45, No. 3, 2005
ACEI, Anemia, and Survival February 1, 2005:391–9eft ventricular systolic dysfunction and symptomatic HF.
sing the SOLVD dataset, we aimed to determine if 1)
nalapril therapy was associated with an increased risk of
ncident anemia after randomization compared to placebo;
) incident anemia, irrespective of etiology, was associated
ith an increased the risk of all-cause mortality; and 3)
nalapril retained its beneficial effects in the setting of
revalent or incident anemia.
ETHODS
full description of the SOLVD trial is published else-
here (11–13). To summarize briefly, the SOLVD trial
onsisted of two parallel trials: a treatment trial and a
revention trial. To be included in either trial, a patient
ust have had a left ventricular ejection fraction 35%.
atients with symptoms of congestive HF were entered in
he treatment trial, whereas asymptomatic patients were
ntered in the prevention trial. All patients were randomly
ssigned to receive either placebo or enalapril. Treatment
ith placebo or enalapril was initiated at 2.5 mg or 5 mg
wice per day and gradually increased to 10 mg twice per
ay, if tolerated. After randomization, all participants were
een after two weeks, six weeks, four months, and then every
our months thereafter until the end of the trial. In
articular, antiplatelet drug use, creatinine, hematocrit, New
ork Heart Association (NYHA) functional class, and
eight were measured at each visit. Hematocrit was mea-
ured at local laboratories during the trial; there were no
uality control measures in place for its measurement. The
urrent study used data from both the treatment trial (n 
,569) and the treatment trial (n  4,228). Because indi-
iduals were randomly assigned to receive either placebo or
nalapril, we performed intent-to-treat analyses, in which
ll participants were included in the treatment group to
hich they were randomized.
The primary objective of the current study was to com-
are the odds of developing new anemia one year after
andomization among patients without prevalent anemia in
he placebo group and in the enalapril group. Consistent
ith the World Health Organization threshold, anemia was
efined by hematocrit 39% in men and 36% in women
14). Prevalent anemia was identified by a hematocrit
easurement below the threshold at randomization,
hereas new anemia was identified by a hematocrit mea-
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
ARB  angiotensin receptor blocker
CI  confidence interval
HF  heart failure
HR  hazard ratio
NYHA  New York Heart Association
OR  odds ratio
SOLVD  Studies Of Left Ventricular Dysfunctionurement below the threshold at one year. Comparisons eere made with and without effects for the change in
reatinine and the change in weight from randomization to
ne year.
Because the comparisons identified anemia at an arbitrary
oint in time and excluded a significant number of patients,
e performed two sensitivity analyses. First, we included all
atients with complete data at randomization and compared
he odds of developing anemia at any time during the trial
mong patients in the placebo group and in the enalapril
roup. In this analysis, anemia included both prevalent
nemia and new anemia at any point after randomization
rather than only at one year). Second, we included all
atients with complete data at randomization, but excluded
atients with prevalent anemia. Then, we compared odds of
eveloping new anemia at any point during the trial.
Additionally, we performed survival analyses to deter-
ine the associations among prevalent and new anemia,
nalapril therapy, and subsequent mortality. Throughout
he analyses, we referred to each interval of time that began
ith a hematocrit measurement below the threshold and
nded with another hematocrit measurement above the
hreshold as an anemia episode. Cox proportional hazards
odels were fitted to estimate the following effects of
nemia episodes and hematocrit on all-cause mortality: 1)
he effect of anemia episodes, regardless of whether episodes
egan at randomization or after randomization; 2) the
ifferential effects of anemia episodes that began at random-
zation and anemia episodes that began after randomization;
nd 3) the effect of hematocrit, a continuous measurement,
ather than anemia, a categorical definition.
In addition to anemia episodes and hematocrit, all models
ncluded time-varying covariates for antiplatelet drug use,
reatinine, NYHA functional class, and weight. A time-
arying covariate in a Cox proportional hazards model may
hange as new measurements are obtained during the course
f a trial. To further account for heterogeneity, we included
n estimated propensity score (15) for anemia episodes in
he applicable Cox models, first as a linear effect, and second
s a set of interaction effects between the tertiles of the
ropensity score and anemia episodes. The results did not
eaningfully differ with either addition of the propensity
core and are not reported.
Follow-up time for all analyses was defined as time
lapsed from randomization to either the death of the
articipant or the end of the trial. Data were analyzed with
AS 8.0 (SAS Institute, Cary, North Carolina). All tests are
resented with two sided p values; values 0.05 were
onsidered significant. The Hennepin County Medical
enter Human Subjects Research Committee approved this
tudy.
ESULTS
he combined SOLVD trials included 6,797 patients. Of
hese, 361 had incomplete data at randomization and were
xcluded from all analyses. Incomplete data at randomiza-
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February 1, 2005:391–9 ACEI, Anemia, and Survivalion were typically marked by a missing value for antiplatelet
rug use, creatinine, hematocrit, NYHA functional class, or
eight, but more rarely by a missing value for age, gender,
r race. Of those with complete data at randomization,
,187 had prevalent anemia. These patients were excluded
rom analyses of only new anemia but were included in other
nalyses. Finally, for analyses of new anemia at one year, we
equired individuals to have complete data at one year; this
esulted in the exclusion of 1,075 patients. Consequently,
ur analyses included 4,174 patients (analyses of new
nemia with adjustment for data at one year), 5,249 patients
analyses of new anemia with adjustment for data at
andomization), or 6,436 individuals (analyses of prevalent
nd new anemia and all survival analyses) (Fig. 1). The
aseline characteristics of those included in our main anal-
sis demonstrated that there were no significant differences
Figure 1. Patient flow diagram.igure 2. Mean hematocrit and 95% confidence interval around mean at eac
lacebo.etween those assigned to the placebo group and to the
nalapril group, as would be expected in a randomized trial.
nalapril and anemia. Compared to placebo, enalapril
herapy was associated with a decrease in hematocrit
Fig. 2). This difference in mean hematocrit was evident as
arly as six weeks after randomization. Figure 3 displays the
umulative hematocrit distribution for the entire SOLVD
opulation. Enalapril use was associated with lower hemat-
crit at one year both among patients with prevalent anemia
nd without prevalent anemia. To better understand
hether the magnitude of hemoglobin change in the ena-
april group compared with the placebo group was driven by
small subset of patients or by the majority of patients, we
ategorized the percentage of individuals with differing
ercentage point changes in hematocrit from baseline to one
ear after randomization (Table 1). A test of association
emonstrated that a greater percentage of individuals ran-
omized to enalapril experienced declines in hematocrit
oncentration at one year compared with individuals ran-
omized to placebo (p  0.0001).
nalapril and the odds of developing new anemia at one
ear. At one year after randomization, 11.3% of those
andomized to enalapril had developed new anemia, com-
ared to 7.9% of those assigned to placebo (unadjusted odds
atio [OR] 1.48, 95% confidence interval [CI] 1.20 to 1.82).
n a logistic model (Table 2) with adjustment for confound-
rs, enalapril continued to be associated with new anemia at
ne year (adjusted OR 1.56, 95% CI 1.26 to 1.93). A
otential confounder of this analysis was that individuals
andomized to enalapril had greater changes in creatinineh follow-up observation among those assigned either to enalapril or to
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ACEI, Anemia, and Survival February 1, 2005:391–9nd weight from randomization to one year than those
andomized to placebo. These changes could have indepen-
ently confounded the association between enalapril and
ew anemia at one year either through dilution (for volume)
r through a decrease in erythropoietin production (for
orsening renal function). To adjust for these potential
onfounders, we included in this model effects for the
hange in creatinine and change in weight from random-
zation to one year. The association between enalapril and
ew anemia was unchanged with the inclusion of these
igure 3. Cumulative distribution of hematocrit at baseline and at one yea
ithout prevalent anemia at baseline; and among those with prevalent a
istributions among those assigned either to enalapril or to placebo.ffects. Enalapril continued to be associated with a 52% increase in the odds of new anemia at one year (OR 1.52,
5% CI 1.22 to 1.89). Increased creatinine (OR 3.56, 95%
I 2.45 to 5.16 per 1-mg/dl increase) and decreased weight
OR 1.03, 95% CI 1.02 to 1.04 per 1-lb decrease) were
ssociated with a significant increase in the odds of devel-
ping new anemia at one year. In both models, the type of
herapy (prevention trial or treatment trial) was not associ-
ted with the odds of developing new anemia at one year.
nalapril and the odds of developing anemia at any time
fter randomization. To assess both the impact of the
ng all Studies Of Left Ventricular Dysfunction participants; among those
at baseline. The p values are displayed for the Wilcoxon test of equalr amo
nemiadentification of anemia at the arbitrary time of one year
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February 1, 2005:391–9 ACEI, Anemia, and Survivalfter randomization and the impact of the exclusion of
atients because of prevalent anemia and incomplete data at
ne year, we performed two sensitivity analyses. For the first
nalysis, we included all patients with complete data at
andomization (n  6,436). Anemia during follow-up
ncluded both prevalent anemia and new anemia at any time
fter randomization (rather than only at one year). Approx-
mately one-half (n  1,187) of the patients with at least
ne anemia episode during follow-up (n  2,466) were
dentified as a result of prevalent anemia. Patients with at
east one anemia episode were more likely to have been
andomized to enalapril and included in the treatment arm
f the SOLVD trial; to have been older and African
merican; and to have had diabetes, a worse NYHA
unctional class score, and a lower weight at randomization
Table 3). Logistic regression (Table 4) demonstrated that
able 1. Percentage of Individuals With Differing Changes in
ematocrit Concentration From Baseline to One Year Stratified
y Treatment Type (n  4,174)
Change in Hematocrit
Placebo
(n  2,086)
Enalapril
(n  2,088) p Value*
ecrease 6 (%) 4.1 5.2 0.0001
ecrease between 4 and 6 (%) 5.4 8.8
ecrease between 2 and 4 (%) 13.8 16.7
ecrease between 0 and 2 (%) 20.9 24.9
o change (%) 13.5 12.8
ncrease between 0 and 2 (%) 22.9 17.9
ncrease between 2 and 4 (%) 11.8 9.6
ncrease between 4 and 6 (%) 4.5 2.7
ncrease 6 (%) 3.1 1.4
Chi-square test.
able 2. Logistic Regression in Those Without Prevalent
nemia at Randomization and With Complete Data at One
ear (n  4,174), Demonstrating the Effect of Enalapril on the
evelopment of New Anemia at One Year, With Adjustment
or Confounders
Parameter
Odds
Ratio 95% CI p Value
nalapril 1.561 (1.261, 1.932) 0.001
rial (reference  prevention)
Treatment 1.167 (0.915, 1.488) 0.213
ge 1.027 (1.015, 1.039) 0.001
ender (reference  female)
Male 1.635 (1.154, 2.317) 0.006
ace (reference  Caucasian)
Black 1.753 (1.263, 2.433) 0.001
Hispanic 1.924 (1.075, 3.443) 0.027
Other (including Native
American)
0.637 (0.227, 1.785) 0.391
reatinine (mg/dl) at
randomization
1.743 (1.168, 2.601) 0.007
iabetes 1.433 (1.100, 1.867) 0.008
jection fraction (%) at
randomization
1.014 (0.997, 1.032) 0.113
YHA functional class at 1 yr
(reference  class I or II)
III or IV 1.959 (1.435, 2.674) 0.001
eight (lbs) at randomization 0.991 (0.988, 0.995) 0.001mI  confidence interval; NYHA  New York Heart Association.nalapril continued to be significantly associated with de-
eloping anemia, but the association was attenuated (OR
.20, 95% CI 1.09 to 1.34). This attenuation was partly
riven by the inclusion of patients with prevalent anemia.
or the second analysis, we included all patients with
omplete data at randomization but excluded patients with
revalent anemia (n  5,249). Anemia during follow-up
ncluded new anemia at any time after randomization. The
dds ratio of developing new anemia at any time after
andomization increased to 1.36 (95% CI 1.20 to 1.55).
mpact of anemia on mortality. To determine the impact
f anemia on survival, we constructed a Cox proportional
azards model with anemia as a time-varying covariate
Table 5). In this model, an anemia episode was associated
ith a 47% increase in the hazard of mortality (hazard ratio
HR] 95%, CI 1.31 to 1.66). To eliminate potential
onfounding between the effects of enalapril and anemia, we
t the same model within each of the two treatment
ubgroups. Among patients receiving placebo, an anemia
pisode was associated with a 56% increase in the hazard of
able 3. Baseline Characteristics of Individuals With No
eriods of Anemia Compared to Individuals With at Least
ne Anemia Episode During the SOLVD Trial
Parameter
No Anemia Episode
During Trial
(n  3,970)
At Least One
Anemia Episode
During Trial
(n  2,466)
nalapril (% of n) 48.2 52.5
rial (% of n)
Prevention 66.7 56.0
Treatment 33.3 44.0
ge (yrs)
Mean (standard deviation) 58.8 (10.2) 61.6 (10.0)
ender (% of n)
Female 13.6 15.2
Male 86.4 84.8
ace (% of n)
Caucasian 87.7 79.4
Black 8.4 16.4
Hispanic 2.2 3.0
Native American 0.4 0.3
Other 0.9 0.6
reatinine (mg/dl) at
randomization
Mean (standard deviation) 1.2 (0.3) 1.2 (0.3)
iabetes (% of n) 16.6 22.9
jection fraction (%) at
randomization
Mean (standard deviation) 27.1 (6.3) 26.9 (6.4)
YHA functional class (% of n)
at randomization
I 49.1 40.6
II 41.1 43.6
III 9.3 15.0
IV 0.5 0.9
eight (lbs) at randomization
Mean (standard deviation) 181.6 (33.6) 171.7 (33.4)
YHA  New York Heart Association; SOLVD  Studies Of Left Ventricular
ysfunction.ortality (HR 95%, CI 1.32 to 1.84), whereas among
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ACEI, Anemia, and Survival February 1, 2005:391–9atients receiving enalapril, an anemia episode was associ-
ted with a 38% increase (HR 95%, CI 1.16 to 1.63). To
ssess further whether this hazard differed between those
ith prevalent anemia and those with incident anemia, we
onstructed a Cox model that included separate effects for
revalent anemia (i.e., anemia episodes that began at ran-
omization) and for new anemia (i.e., anemia episodes that
egan after randomization). Prevalent anemia was associ-
ted with a 44% increase in the hazard of mortality (HR
5%, CI 1.27 to 1.64), compared to a 108% increase in the
azard of mortality associated with new anemia (HR 95%,
I 1.82 to 2.38). In both of the models that included all
atients with complete data at randomization, enalapril
Table 4. Logistic Regression in all SOLVD Pa
(n  6,436), Demonstrating the Effect of Ena
Time During the Trial, With Adjustment for
Parameter
Enalapril
Trial (reference  prevention)
Treatment
Age
Gender (reference  female)
Male
Race (reference  Caucasian)
Black
Hispanic
Other (including Native American)
Creatinine (mg/dl) at randomization
Diabetes
Ejection fraction (%) at randomization
NYHA functional class at randomization
(reference  class I or II)
III or IV
Weight (lbs) at randomization
Abbreviations as in Table 3.
able 5. Results of Adjusted Cox Regression of All-Cause Morta
Parameter
All Patients (n  6,436
HR 95% CI
nemia episode 1.472 (1.309, 1.65
nalapril 0.885 (0.799, 0.97
rial (reference  prevention)
Treatment 1.335 (1.182, 1.50
ge (yrs) 1.008 (1.003, 1.01
ender (reference  female)
Male 1.292 (1.111, 1.50
ace (reference  Caucasian)
Black 1.088 (0.942, 1.25
Hispanic 0.751 (0.527, 1.06
Other (including Native American) 1.073 (0.721, 1.59
ntiplatelet drug use 0.719 (0.646, 0.80
reatinine (mg/dl) 1.501 (1.359, 1.65
iabetes 1.277 (1.131, 1.44
jection fraction (%) at randomization 0.964 (0.957, 0.97
YHA class (reference  class I)
II 1.555 (1.354, 1.78
III 2.876 (2.429, 3.40
IV 8.922 (7.035, 11.3
eight (lbs) 0.995 (0.994, 0.99I  confidence interval; HR  hazard ratio; NA  not applicable.herapy was associated with a decreased risk of mortality
ompared to placebo, with a magnitude of benefit similar to
hat found in the original SOLVD study. In particular, all
nteraction effects between enalapril and anemia (including
nemia episodes, prevalent anemia, and incident anemia)
ailed to achieve significance and were not included in the
eported models.
mpact of time-varying hematocrit on mortality. Because
he World Health Organization threshold for the definition
f anemia is arbitrary, and because the effect of hematocrit
n mortality is likely linear, we constructed a Cox model
ith hematocrit, rather than anemia, as a time-varying
ovariate (Table 6). After adjustment for the effects of
pants With Complete Data at Randomization
on the Development of Anemia at Any
ounders
Ratio 95% CI p Value
204 (1.085, 1.337) 0.001
274 (1.124, 1.446) 0.001
019 (1.013, 1.025) 0.001
243 (1.057, 1.462) 0.009
156 (1.824, 2.548) 0.001
318 (0.951, 1.828) 0.097
718 (0.455, 1.132) 0.154
906 (1.569, 2.314) 0.001
400 (1.223, 1.604) 0.001
011 (1.002, 1.020) 0.015
301 (1.088, 1.556) 0.004
990 (0.989, 0.992) 0.001
y Anemia Episode During the Trial
Placebo (n  3,228) Enalapril (n  3,208)
HR 95% CI HR 95% CI
1.562 (1.324, 1.843) 1.376 (1.162, 1.629)
NA NA
1.398 (1.183, 1.653) 1.291 (1.080, 1.543)
1.006 (0.999, 1.013) 1.012 (1.003, 1.020)
1.188 (0.967, 1.459) 1.453 (1.164, 1.815)
1.079 (0.884, 1.318) 1.102 (0.893, 1.361)
0.965 (0.602, 1.547) 0.580 (0.340, 0.989)
1.352 (0.822, 2.224) 0.776 (0.401, 1.502)
0.692 (0.596, 0.802) 0.741 (0.635, 0.865)
1.533 (1.327, 1.771) 1.461 (1.274, 1.675)
1.238 (1.049, 1.461) 1.340 (1.119, 1.605)
0.958 (0.948, 0.968) 0.972 (0.960, 0.983)
1.665 (1.369, 2.026) 1.447 (1.189, 1.761)
2.695 (2.126, 3.417) 3.121 (2.453, 3.971)
8.412 (6.019, 11.76) 9.369 (6.678, 13.15)
0.998 (0.995, 1.000) 0.993 (0.990, 0.995)rtici
lapril
Conf
Odds
1.
1.
1.
1.
2.
1.
0.
1.
1.
1.
1.
0.lity b
)
7)
9)
8)
4)
1)
7)
9)
7)
0)
8)
2)
2)
7)
5)
2)
7)
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February 1, 2005:391–9 ACEI, Anemia, and Survivalonfounders, each percentage point increase in hematocrit
as associated with a 3% reduction in mortality (HR 0.97,
5% CI 0.96 to 0.98). Again, we fit the same model within
ach of the two treatment subgroups. Among patients
eceiving placebo, each percentage point increase in hemat-
crit was associated with a 3% reduction in mortality (HR
.97, 95% CI 0.95 to 0.98), whereas among patients
eceiving enalapril, each percentage point increase in hemat-
crit was associated with a 2% reduction (HR 0.98, 95% CI
.96 to 1.00). Enalapril continued to be associated with a
urvival benefit (HR 0.89, 95% CI 0.80 to 0.98). Similar to
reviously described models, the interaction effect between
nalapril and hematocrit failed to achieve significance, and
as not included in the reported model.
ISCUSSION
tilizing data from both the SOLVD prevention trial and
reatment trial, we have demonstrated that prevalent anemia
s common in the HF population. Anemia was present in
8.4% of the SOLVD trial participants at randomization. In
ddition, after excluding prevalent cases, incident cases of
nemia at one year occurred in 9.6% of the population. In an
ntent-to-treat model, use of enalapril increased the odds of
ew anemia at one year by 56%. This association persisted
hen the change in creatinine and weight were included as
ffects. However, this association was attenuated when
ndividuals with prevalent anemia were included in the
nalysis. An anemia episode was significantly associated
ith an increased risk of mortality (HR 1.47). This risk
ppeared to differ depending on whether the anemia was
resent at randomization (HR 1.44) versus whether the
nemia was incident after randomization (HR 2.08). De-
able 6. Results of Adjusted Cox Regression of All-Cause Morta
Parameter
All Patients (n  6,436
HR 95% CI
ematocrit 0.973 (0.963, 0.98
nalapril 0.885 (0.799, 0.97
rial (reference  prevention)
Treatment 1.342 (1.188, 1.51
ge (yrs) 1.009 (1.003, 1.01
ender (reference  female)
Male 1.419 (1.218, 1.65
ace (reference  Caucasian)
Black 1.090 (0.943, 1.26
Hispanic 0.761 (0.534, 1.08
Other (including Native American) 1.053 (0.708, 1.56
ntiplatelet drug use 0.716 (0.644, 0.79
reatinine (mg/dl) 1.508 (1.366, 1.66
iabetes 1.288 (1.140, 1.45
jection fraction (%) at randomization 0.965 (0.957, 0.97
YHA class (reference  class I)
II 1.556 (1.355, 1.78
III 2.899 (2.449, 3.43
IV 9.103 (7.177, 11.5
eight (lbs) 0.995 (0.994, 0.99
bbreviations as in Tables 3 and 5.pite the increase in anemia, enalapril use overall continued to be associated with a survival benefit, even among those
ith prevalent anemia at baseline. We did not evaluate
hether there existed a dose response between the incidence
f anemia and the dose of enalapril utilized, as the enalapril
ose was determined by clinical factors and individualized to
ach participant. Any attempt at delineating a dose response
ould have been confounded by the individual’s clinical
ircumstance.
The occurrence of a decline in hematocrit demonstrated
n our study is consistent with the decline in hemoglobin
stablished in other studies. These studies have shown that
CEIs reduce hemoglobin concentrations in healthy indi-
iduals (16), those receiving dialysis (17), those with post-
ransplant erythrocytosis (7,8,10,18–21), and in those with
igh-altitude polycythemia (9). Although these studies have
emonstrated an association between ACEI use and a
ecline in hemoglobin concentration, the majority have
een either case series or small crossover studies of short
uration. We have demonstrated for the first time, in the
etting of a large randomized controlled trial, that admin-
stration of enalapril to individuals with HF and normal
ematocrit values was associated with an increased inci-
ence of anemia at one year. As shown in Figure 2, this
eduction in hematocrit is seen as early as six weeks after
nitiating therapy and is sustained for the duration of the
rial. The effect of enalapril on hemoglobin is modest and
ppears to affect only a selected population.
The mechanism by which ACEIs cause anemia remains
nclear. There have been numerous attempts to delineate
he pathophysiology in patients with post kidney transplant
olycythemia. In vitro studies have demonstrated that an-
iotensin II stimulates erythroid precursors through activa-
y Time-Varying Hematocrit During the Trial
Placebo (n  3,228) Enalapril (n  3,208)
HR 95% CI HR 95% CI
0.968 (0.954, 0.983) 0.980 (0.964, 0.996)
NA NA
1.406 (1.190, 1.662) 1.296 (1.084, 1.550)
1.006 (0.999, 1.014) 1.012 (1.004, 1.020)
1.320 (1.072, 1.626) 1.566 (1.250, 1.961)
1.083 (0.886, 1.323) 1.106 (0.895, 1.367)
0.967 (0.603, 1.550) 0.592 (0.347, 1.008)
1.328 (0.808, 2.185) 0.763 (0.394, 1.477)
0.692 (0.597, 0.802) 0.735 (0.629, 0.858)
1.549 (1.338, 1.792) 1.466 (1.280, 1.678)
1.249 (1.059, 1.474) 1.351 (1.128, 1.618)
0.959 (0.949, 0.969) 0.972 (0.961, 0.983)
1.662 (1.366, 2.023) 1.450 (1.191, 1.764)
2.701 (2.130, 3.424) 3.161 (2.484, 4.022)
8.599 (6.156, 12.01) 9.511 (6.772, 13.36)
0.998 (0.995, 1.000) 0.992 (0.990, 0.995)lity b
)
4)
9)
6)
4)
2)
0)
3)
7)
7)
4)
4)
2)
7)
3)
5)
7)ion of an AT1 receptor on blast-forming units—erythroid
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ACEI, Anemia, and Survival February 1, 2005:391–922,23). Use of ACEIs decreases circulating angiotensin II
evels with subsequent inhibition of erythroid precursors. In
ddition, other studies have demonstrated that ACEIs
ower insulin growth factor levels (8,24), which have been
ssociated with erythroid stimulation. Finally, ACEIs in-
ibit catabolism of N-acetyl-seryl-aspartyl-proline, a natural
eptide that decreases proliferation of red cell precursors
25).
Anemia is associated with a significantly increased risk of
eath in those with either asymptomatic left ventricular
ystolic dysfunction or symptomatic HF. Prevalent anemia
t the initiation of the SOLVD study has previously been
emonstrated to be an independent risk factor for cardio-
ascular and all-cause mortality (5). Additionally, four large
pidemiologic studies have demonstrated that anemia is a
isk factor for hospitalization as well as mortality (4,26–28).
oreover, anemia is an independent predictor of death in
everely ill HF patients awaiting heart transplantation (29),
n those admitted to the hospital with myocardial infarc-
ions (30), and in dialysis patients (31). Prior studies have
een limited in that all assessed the impact of prevalent
nemia on outcome. We have demonstrated that a relatively
hort duration of incident anemia is associated with an
ncreased risk of mortality.
There are several limitations to our study results. For the
rst part of the study, participants were analyzed using an
ntent-to-treat rule, and more than 1,200 individuals were
xcluded because of prevalent anemia, potentially biasing
he results obtained. However, because exclusion was per-
ormed before any analysis and participants were excluded
n the basis of a pre-randomization variable, and our
ensitivity analysis was consistent with our primary results,
e feel that these exclusions had minimal impact on our
esults. Additionally, the World Health Organization def-
nition for anemia is based on measured hemoglobin,
hereas our results are based on hematocrit, though we are
naware of any systematic bias between the two. For the
urvival analysis, participants were not analyzed on the basis
f the group to which they were randomized. Results from
his section should be interpreted as if they had been derived
rom a cohort study. Many pre-one-year visit factors dif-
ered significantly between those who developed anemia and
hose who did not, as demonstrated in Table 3. We have
ttempted to adjust for possible confounders; however, there
ay exist other factors that were not measured and could be
nfluencing our study results (such as blood transfusions). It
ay simply be that anemia is an early marker of those that
re likely to die from their HF and bears no etiologic role in
he morbidity and mortality of HF. Because of power
imitations we were unable to determine if individuals who
eveloped anemia attributable to enalapril had a poorer
urvival than those who did not develop anemia on enala-
ril. Also, because of the design of our study we are not able
o address whether individuals that develop incident anemia
s a results of ACEI therapy should have their ACEIs
ithheld. However, we did demonstrate that in those withrevalent anemia at baseline, use of enalapril was associated
ith a significant survival advantage similar to the magni-
ude originally described (12,13). Finally, hematocrit was
ot centrally measured and there were no quality control
easures in place to determine the accuracy of reported
ematocrit values.
Small randomized controlled trials have demonstrated
hat correction of mild anemia in patients with HF resulted
n improved cardiac and patient function (31,33), as well as
educed overall hospitalizations. Anemia appears to be an
nder-recognized risk factor for both morbidity and mor-
ality in those with established HF. Given the current
vidence, there ought to be a large, randomized placebo-
ontrolled trial to determine if anemia correction and/or
revention in those with HF can reduce the associated
orbidity or mortality.
onclusions. Incident anemia at one year is common in
hose with reduced left ventricular function. Treatment with
nalapril increases the odds of anemia at one year. Partici-
ants with anemia had an increased mortality risk compared
ith those that never develop anemia. This risk is magnified
n those with incident anemia as compared to those with
revalent anemia. Enalapril was protective of overall mor-
ality after adjusting for incident anemia and in those with
revalent anemia.
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